

Development of third-generation antibody-drug conjugate linker technology capable of site-selectively conjugating payloads without antibody modification

AbTis Co., Ltd



ONCOLOGY	Lead
Product Type	Small Molecules, Antibody Drug Conjugate(ADC)
Indication	Target antigen-positive gastric cancer, breast cancer, lung cancer and pancreatic cancer etc.
Target	Antigen present on the surface of cancer cells (Ex. HER2, HER3, Nectin-4, Claudin 18.2, Trop-2, EGFR etc.)
MoA(Mechanism of Action)	Binding to target antigen → Internalization → Cleaved and released cytotoxic payload in lysosome → Cancer cell death by released payload
Competitiveness	<ul style="list-style-type: none"> • Site-selective ADC obtained with controllable DAR and improved homogeneity • Native antibody can be used without need for engineering or glycan remodeling • Stable isopeptide bond formed between protein and linker • Simple process 2-step process with high yield • Applicable to different IgG subtypes
Development Stage	Lead
Route of Administration	IV infusion